Loading stock data…
Phreesia (PHR)
$10.29+0.22 (+2.18%)
Market ClosedLast close Jun 29
Phreesia, Inc.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Phreesia, Inc. in the Healthcare sector is trading at $10.29 with a market capitalization of $562M. Wall Street consensus targets $13.94 (17 analysts), implying a +35.5% move over the next 12 months. The stock is currently near its 52-week low of $7.77, remaining 32.0% below its 200-day moving average. On fundamentals, Piotroski 5/9 shows mixed financial quality, Altman Z in the distress zone. The Whystock Score of 40/100 suggests a balanced risk-reward profile.
Ecosystem Influences
Sell-side targets imply +35.5% upside over 12 months
Long-term trend bearish (price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Quarterly Financials
| Metric (USD) | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 |
|---|---|---|---|---|---|
| Total Revenue | $130.94M↑ | $127.07M↑ | $120.33M↑ | $117.25M↑ | $115.94M |
| Gross Profit | $87.60M↑ | $86.68M↑ | $82.31M↑ | $79.61M↑ | $77.87M |
| Operating Income | $6.75M↑ | -$5.56M↓ | $3.74M↑ | -$1.51M↑ | -$3.29M |
| Net Income | $2.96M↑ | $1.29M↓ | $4.27M↑ | $654,000↑ | -$3.91M |
Peer Comparison
JNJUNHPFE
Fundamentals
Phreesia, Inc. provides an integrated SaaS-based software and payment platform for the healthcare industry in the United States and Canada. It offers solutions including appointment optimization and referral management using AI-enabled workflows; and...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$561.87M
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
-
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
2.56%
Volume
Today's trading volume
1.33M
Recent News
Phreesia (PHR) Stock Fair Value Edges Lower As Analysts Split On Growth Outlook
Phreesia just saw its modeled fair value nudged lower, with the price target trimmed from US$14.28 to US$13.94, a reduction of about 2.4%. That shift lines up with recent Street research, where price targets now tend to sit in the high single digits to mid teens and many ratings cluster around Neutral or Equal Weight as analysts weigh growth visibility against execution. Read on to see what is driving this evolving Phreesia story and how you can keep track of the changing narrative around the...
Phreesia's (NYSE:PHR) Strong Earnings Are Of Good Quality
When companies post strong earnings, the stock generally performs well, just like Phreesia, Inc.'s ( NYSE:PHR ) stock...
Are Investors Undervaluing Phreesia (PHR) Right Now?
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Do You Believe in Phreesia’s (PHR) Strong Upside Potential?
Cambiar SMID Fund, managed by Cambiar Investors, published its Q1 2026 investor letter. A copy of the letter is available to download here. The investor class (CAMMX) returned 2.21%, and the institutional class (CAMUX) returned 2.27%, underperforming the Russell 2500 Value Index’s 4.77%. This shortfall was mainly due to declines in certain healthcare and industrial […]
Phreesia Inc (PHR) Q1 2027 Earnings Call Highlights: Strong Revenue Growth and Positive Net ...
Phreesia Inc (PHR) reports a 13% revenue increase and a positive net income, driven by robust growth in payment solutions and strategic financial moves.